BRPTO publishes a study about RNA vaccines to prevent COVID-19

The Observatory of Technologies Associated with COVID-19, from BRPTO, published on Monday, December 14, a study entitled Panorama of patent documents related to RNA vaccines in clinical trials for the prevention of COVID-19.

The study aims to provide an overview of current knowledge related to RNA vaccines in a more advanced clinical stage, based on patent documents related to these technologies. In addition to serving as a source of technological information, the work makes it possible to learn about patent applications filed at BRPTO and around the world.

The information provided in the study can also help future measures, both in the public and private spheres, particularly if these vaccines prove to be effective in preventing SARS-CoV-2 infection. The six candidates for RNA-based vaccines that have been in clinical trials to date have been selected.

This study is part of a series of publications on vaccines in more advanced clinical trials.

The DNA-Based Vaccines study for the prevention of COVID-19: Mechanism of action, clinical trials and patent applications has already been published and new studies will include vaccines based on viral vectors, inactivated viruses and protein subunits.

The study can also serve as a source of technological information and the work makes it possible to learn about patent applications filed at BRPTO and around the world.